NEW YORK (GenomeWeb News) – Sangamo BioSciences and Sigma-Aldrich said today that Roche has licensed Sangamo’s zinc finger nuclease technology to develop cell lines and transgenic animals that have targeted modifications in specific genes.
 
Zinc finger nucleases are engineered forms of zinc finger DNA-binding proteins that can be used to help modify target genes in organisms. Sigma-Aldrich is the exclusive licensee of Sangamo’s ZFN technology for research reagents.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.